GPX4 Inhibitor Resistance and Metastatic Features in Triple‐Negative Breast Cancer
Advanced Science · 2026-04 · 13 (23)
DOI: 10.1002/advs.202523198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 17.02.2026. Verfasst von Marie Sabatier und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Phospholipid Hydroperoxide Glutathione Peroxidase, Triple Negative Breast Neoplasms, Ferroptosis, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Senatsverwaltung für Wissenschaft, Gesundheit und Pflege Berlin, The Ludwig Center at Harvard (J.M.U.), NIH/NCI 1R01CA282202 (J.M.U.).
Abstract (Originalsprache)
Leveraging ferroptosis as a cancer therapy has faced challenges due to the limited bioavailability and systemic toxicities of small‐molecule ferroptosis modulators. Small molecule inhibitors such as RSL3 and ML210 trigger ferroptosis by targeting glutathione peroxidase 4 (GPX4), a key enzyme that neutralizes lipid peroxides. While many studies have focused on targeting primary tumors, much less is known about the extent to which GPX4‐inhibitor resistance may contribute to metastasis. To address this, we cultured triple‐negative breast cancer cell lines with GPX4 inhibitors to generate cell lines (M231, 4T1) that were resistant to GPX4 inhibitors (GPX4i). Tumors derived from GPX4i‐resistant cells compared to parental cells had unique metabolic and lipidomic profiles, were associated with a shift toward an epithelial‐like state (decreased vimentin, increased EpCAM expression), formed decreased spontaneous metastases from primary tumors, but had no differences in overall metastatic burden upon intravenous injection. Collectively, these data demonstrate that long‐term maintenance with GPX4‐inhibitors in vitro leads to altered metastatic profiles in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Leibniz-Institut Für Analytische Wissenschaften - ISAS - E.V., Dortmund, Germany.
- Department of Dermatology, University Hospital Essen & German Cancer Consortium (DKTK), Essen, Germany.
- Lipidomics, Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany.
- Ludwig Center at Harvard, Boston, Massachusetts, USA.
ORCID-Profile: Marie Sabatier, Jessalyn M Ubellacker
Förderung
- Senatsverwaltung für Wissenschaft, Gesundheit und Pflege Berlin
- The Ludwig Center at Harvard (J.M.U.)
- NIH/NCI 1R01CA282202 (J.M.U.)
- Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)
- Cause Breast Cancer Foundation (J.M.U.)
- NCI NIH HHS
- Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen
Zitieren
APA
Sabatier, M., Kaur, M., Chaufan, M., Hormann, F. L., Melo, L. M. N., Palma, M., Torpey, J., Liang, Y., Carmona, A., Fraser, C., Flores, M., Szylo, K. J., Yavari, M., Hui, S., Tasdogan, A., Heiles, S., & Ubellacker, J. M. (2026). GPX4 Inhibitor Resistance and Metastatic Features in Triple‐Negative Breast Cancer. Advanced Science, 13(23). https://doi.org/10.1002/advs.202523198
Vancouver
Sabatier M, Kaur M, Chaufan M, Hormann FL, Melo LMN, Palma M, et al. GPX4 Inhibitor Resistance and Metastatic Features in Triple‐Negative Breast Cancer. Advanced Science. 2026;13(23). doi:10.1002/advs.202523198
BibTeX
@article{Sabatier2026,
author = {Sabatier, Marie and Kaur, Mayher and Chaufan, Milena and Hormann, Felix-Levin and Melo, Luiza Martins Nascentes and Palma, Mario and Torpey, Jordan and Liang, Yanshan and Carmona, Alanis and Fraser, Cameron and Flores, Midori and Szylo, Krystina J and Yavari, Mahsa and Hui, Sheng and Tasdogan, Alpaslan and Heiles, Sven and Ubellacker, Jessalyn M},
title = {GPX4 Inhibitor Resistance and Metastatic Features in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {23},
doi = {10.1002/advs.202523198}
}
EUVIMED